Here's What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock [Yahoo! Finance]
Relmada Therapeutics, Inc. (RLMD)
NASDAQ:AMEX Investor Relations:
ir.relmada.com
Company Research
Source: Yahoo! Finance
has several potential drugs at various stages of development. Its psychedelic drug candidate REL-P11 has completed a Phase 1 safety study as a potential treatment for metabolic diseases. REL-P11 is based on a formulation of a hallucinogenic substance called psilocybin. The company's other drug candidate NDV-01 is being developed as a treatment for an aggressive form of bladder cancer. Here's What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock Pressmaster/Shutterstock.com On March 9, Mizuho reiterated its Outperform rating and $10 price target on Relmada Therapeutics stock. The firm pointed to the Phase 2 trial results for NDV-01 for its renewed bullish stance on the stock. The 12-month data from the study showed positive results. When it comes to assessing durability in a clinical program, a 12-month trial data readout is considered the gold standard. Moreover, this timeframe is also the FDA benchmark when it comes to evaluating efficacy in the form of bladder can
Show less
Read more
Impact Snapshot
Event Time:
RLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLMD alerts
High impacting Relmada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLMD
News
- Relmada Therapeutics (RLMD) is now covered by Piper Sandler. They set an "overweight" rating and a $12.00 price target on the stock.MarketBeat
- Relmada Therapeutics (RLMD) had its price target raised by Mizuho from $10.00 to $19.00. They now have an "outperform" rating on the stock.MarketBeat
- Relmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Highlights: Strategic Advancements and ... [Yahoo! Finance]Yahoo! Finance
- Relmada (RLMD) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Relmada Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
RLMD
Earnings
- 3/19/26 - Miss
RLMD
Sec Filings
- 3/20/26 - Form 8-K
- 3/19/26 - Form 10-K
- 3/9/26 - Form 8-K
- RLMD's page on the SEC website